Company / Shareholders' Equity
Cullinan Therapeutics, Inc. Shareholders' Equity History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$590.3M
FY2024
5-year range
$200.3M / $590.3M
FY2020-FY2024
Trend
+30.1%
vs FY2023
Sector context
#83 of 213
Health Care
What the data says
At $590M, Cullinan Therapeutics, Inc.'s shareholders' equity ranks #83 of 213 in the Health Care sector. Improved from $535M to $590M over the past 2 years.
Based on SEC 10-K filings.
$590M in FY2024 with a 3-year CAGR of +11.6%.
Improved from $535M to $590M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +11.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#83 of 213 in Health CareTop 39% of 213This company $590.3M Sector average $2.5B
▼
-76.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +11.6%, indicating consistent growth.
- In FY2024, shareholders' equity increased 30.1% year-over-year.
- Ranks #83 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $590.3M | +30.1% |
| FY2023 | $453.7M | -15.2% |
| FY2022 | $535.0M | +25.9% |
| FY2021 | $425.0M | +112.2% |
| FY2020 | $200.3M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026